(Q43865449)

27 November 2017

title

An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model (English)

1 reference

27 November 2017

0 references

1 reference

Masliah E

1 reference

27 November 2017

Hashimoto M

1 reference

27 November 2017

Rockenstein E

1 reference

27 November 2017

Mante M

1 reference

27 November 2017

Crews L

1 reference

27 November 2017

Bar-On P

1 reference

27 November 2017

Gage FH

1 reference

27 November 2017

Marr R

1 reference

27 November 2017

publication date

1 December 2004

1 reference

27 November 2017

1 reference

27 November 2017

1 reference

27 November 2017

1 reference

27 November 2017

page(s)

1713-1723

1 reference

Gene therapy progress and prospects: Parkinson's disease

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Alpha-synuclein in Lewy body disease and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Amyloid diseases: abnormal protein aggregation in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Membrane binding and self-association of alpha-synucleins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

The rat brain synucleins; family of proteins transiently associated with neuronal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Lentiviral vectors: regulated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Chaperone-like activity of synucleins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

alpha-Synuclein forms a complex with transcription factor Elk-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

The role of polyunsaturated fatty acids in restoring the aging neuronal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

7 January 2021

Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

7 January 2021

Oxidative stress, mitochondrial respiration, and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

7 January 2021

Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

7 January 2021

Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

7 January 2021

High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302349

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302349

1 reference

Dimensions Publication ID

27 November 2017

1028930868

0 references

1 reference